CKCilmara Kuwahara

Cilmara Kuwahara

*This is an algorithmically generated author record based on publicly available information.

Cilmara Kuwahara has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current use and outcomes of cellular therapy: Brazilian Summary Slides – 2026

    by Cinthya Corrêa da Silva, Anderson João Simione, Giancarlo Fatobene, Jayr Schmidt Filho, Adriana Seber, Nelson Hamerschlak, João Samuel de Holanda Farias, Vaneuza Araújo Moreira Funke, Phillip Scheinberg, Maria Claudia Rodrigues Moreira, et al.

    Objective: To describe CAR-T cell therapy activity and outcomes reported by Brazilian centers participating in the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO)/Center for International Blood and Marrow Transplant Research (CIBMTR) network between January 2020 and December 2025. Methods: Data from patients who received commercial or academic CAR-T cell therapies in Brazilian centers were extracted from the CIBMTR database. Participating centers reported data through the FormsNet3 platform, allowing standardized collection of patient, disease, and treatment-related variables. Descriptive analyses were performed, and overall survival (OS) was estimated using the Kaplan–Meier method. Results: A total of 219 CAR-T cell infusions were reported. The median age was 57 years (range, 4–83 years). The most common indications were non Hodgkin lymphoma (NHL) (146 patients, 67%), multiple myeloma (MM) (39 patients, 18%), acute lymphoblastic leukemia (ALL) (32 patients, 14%), and chronic lymphocytic leukemia (CLL) (2 patients, 1%). Commercial CAR-T products accounted for 89% of all treatments and were predominantly used for NHL (n = 135) and MM (n = 35). Most deaths were attributed to disease progression or relapse (n = 42), followed by infections (n = 14). After a median followup of 365 days, the 1-year OS was 63% (95% CI, 54–73%) among patients with NHL and 73% (95% CI, 57–93%) among patients with ALL. Conclusion: This report documents the implementation and rapid expansion of CAR-T cell therapy in Brazil among centers reporting to the SBTMO/CIBMTR network. The continued development of this collaborative infrastructure supports national monitoring of CAR-T activity, facilitates outcome assessment, and contributes to quality assurance, benchmarking initiatives, and compliance with national and international regulatory requirements.

  • Open Access

    Consensus in stem cell transplantation for pediatric lymphomas

    by Cilmara Kuwahara, Carla Nolasco Monteiro Breviglieri, Luiza Milaré, Osvaldo Alves Menezes Neto

    Lymphomas are the third most common childhood cancer in Brazil. Management is predicated on precise diagnosis and staging through clinical, pathological, molecular, and radiological evaluation. Although the prognosis for pediatric non-Hodgkin and Hodgkin lymphoma has improved markedly, relapsed or refractory cases remain a clinical challenge. For these patients, aggressive chemotherapy followed by autologous or allogeneic hematopoietic cell transplantation serves as a vital salvage strategy. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This revision also includes the assessment of new therapeutic strategies, including immunotherapy and CAR-T cell therapy, for eligible patients.

  • Open Access

    Hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia

    by Liane Esteves Daudt, Ana Carolina Ribeiro Correa, Antonella Zanette, Antonio Vaz de Macedo, Carla Nolasco Monteiro Breviglieri, Cilmara Kuwahara, Cláudio Galvão de Castro Junior, Luciana dos Santos Domingues, Paulo Klinger, Maura Ikoma, et al.

    This article details the 2025 consensus update from the Brazilian Group for Pediatric Bone Marrow Transplantation and the Brazilian Society for Pediatric Oncology regarding hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL). Allogeneic HSCT is the standard treatment for high-risk or relapsed ALL. Key indications include, in first remission, very high risk patients defined by primary induction failure or positive minimal residual disease (MRD) after consolidation. In second remission, it is indicated for early bone marrow relapse, early isolated extramedullary B-cell relapse, and all T-cell ALL relapses. The consensus recommends myeloablative conditioning as standard, preferring total body irradiation based regimens for children over 2–3 years old. The preferred donor hierarchy is a matched sibling, followed by a matched unrelated donor, with bone marrow being the preferred cell source. Post-HSCT monitoring of MRD is critical for guiding interventions and identifying relapse. This document serves as an essential, updated guide for clinical decision-making in this field.

  • Open Access

    Consensus in stem cell transplantation for pediatric solid tumors

    by Cilmara Kuwahara, Simone Franco, Luiza Milaré, Cláudio Galvão de Castro Junior, Adriana Seber

    Solid tumors in the pediatric population are preferred treated in clinical national or international protocols, in which the work of pediatric oncology cooperative groups guides the therapeutic standards and advancements. The role of high-dose chemotherapy (HDC) and hematopoietic cell transplant (HCT) in the pediatric population is usually reserved for patients or subgroups of patients who have diseases with poor prognosis and sometimes are refractory to the best available treatment, in combination to conventional chemotherapy, surgical procedure, and radiation. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This updated guidance emphasizes that, while HDC/HCT is an important tool for specific high-risk malignancies, several tumors continue to have no indication for autologous transplantation based on current evidence.

  • Open Access

    Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus

    by Luiz Guilherme Darrigo Junior, Ana Karine Vieira, Cilmara Kuwahara, Roseane Vasconcelos Gouveia, Paulo Klinger, Alexandre de Albuquerque Antunes, Julia Lopes Garcia

    Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.

  • Open Access

    Sickle cell disease

    by Luiz Guilherme Darrigo Junior, Roseane Vasconcelos Gouveia, Cilmara Kuwahara, Alexandre de Albuquerque Antunes, Adriana Martins de Sousa, Ana Karine Vieira, Ainá Henriques Melgaço, Juliana Folloni Fernandes, Adriana Seber

    Sickle cell disease (SCD) is known as the most common hemoglobin disorder, with severe forms of thalassemia syndromes following closely. Current standard treatments, including transfusions, hydroxyurea, and L-glutamine, still do not significantly improve life expectancy and quality of life for patients. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative option, showing overall survival and event-free survival rates over 90%, especially in patients under 16 years old. However, only 15% of SCD patients have access to an unaffected family donor. To increase donor availability, alternative sources such as matched unrelated donors, unrelated umbilical cord blood, and haploidentical donors have become viable options for patients without a matched related donor. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of patients with SCD undergoing HCT.

  • Open Access

    Central nervous system tumors

    by Gustavo Zamperlini, Paulo Henrique dos Santos Klinger, Antonella Zanette, Cilmara Kuwahara, Sidnei Epelman, Adriana Seber, Cláudio Galvão de Castro Junior

    Central nervous system (CNS) tumors represent one of the most prevalent groups of neoplasms in the pediatric population. Recent advances in molecular biology and neuro-oncology have led to continuous updates in the classification of these tumors, which poses significant diagnostic challenges, particularly in low- and middle-income countries, with limited access to advanced diagnostic tools. The therapeutic approach varies according to tumor subtype, often requiring complex and resource-intensive protocols. One such strategy involves the use of high-dose chemotherapy followed by autologous stem cell rescue, which has shown promise in improving outcomes for select pediatric patients with CNS tumors. However, implementation of this therapy in countries like Brazil faces logistical, financial, and clinical practice challenges. This article aimed to provide a brief overview and suggestions to use high-dose chemotherapy with autologous stem cell transplantation in the treatment of pediatric CNS tumors. We discussed practical considerations for patient selection, and conditioning regimens. Our objectives were to optimize and guide current practices by proposing strategies that maybe feasible in the Brazilian public and private healthcare systems.

  • Open Access

    CAR-T cell therapies

    by Antonella Zanette, Adriana Martins de Sousa, Cilmara Kuwahara, Mariane Farherr Caleffi, Natalia Maria Tavares Ferreira Borges, Adriana Seber, Julia Lopes Garcia

    Chimeric antigen receptor T-cell (CAR-T) therapy has rapidly reshaped the therapeutic landscape for children and adolescents with relapsed or refractory hematologic malignancies. In Brazil, the integration of CAR-T therapy into pediatric oncology practice faces unique logistical, regulatory, and socioeconomic challenges, highlighting the need for structured, context-specific guidance. This national pediatric consensus summarizes current evidence and provides practical recommendations for indications, leukapheresis, washout strategies, bridging therapy, lymphodepletion, infusion procedures, and the management of toxicities, including cytokine release syndrome, immune effector cellassociated neurotoxicity syndrome, coagulopathy, and HLH-like syndromes. Long-term follow-up, immune reconstitution monitoring, vaccination guidance, and survivorship considerations are also addressed. Emerging applications in myeloid malignancies, T-cell neoplasms, and solid tumors—particularly GD2-targeted CAR-T cells for neuroblastoma—are briefly reviewed. By consolidating multidisciplinary expertise from institutions across Brazil, this document sought to support safe, effective, and equitable implementation of CAR-T therapy in the pediatric population and encourages continued development of local manufacturing and academic protocols to expand access to this transformative treatment.

  • Open Access

    Immune reconstitution after allogenic stem cell transplantation: An observational study in pediatric patients

    by Aline Risson Belinovski, Polliany Dorini Pelegrina, Alberto Cardoso Martins Lima, Cilmara Cristina Kuwahara Dumke, Adriana Mello Rodrigues, Gisele Loth, Fernanda Moreira de Lara Benini, Ana Luiza Melo Rodrigues, Fábio Araujo Motta, Carolina Prando, et al.